Breast Implant-Associated Cancers
Two rare but serious cancers are associated with breast implants: BIA-ALCL and BIA-SCC. Both arise within the scar tissue capsule surrounding the implant. When explant surgery is performed for a suspected or confirmed implant-associated cancer, complete oncologic removal is critical. Both conditions are treated with en bloc capsulectomy — and surgical outcome depends directly on whether that procedure is performed correctly.
Dr. Robert Whitfield, MD • Austin, Texas • 2,000+ Explant Procedures
What Are Breast Implant-Associated Cancers?
The U.S. FDA and the National Comprehensive Cancer Network (NCCN) recognize three distinct malignancies that can develop in the tissue surrounding breast implants — BIA-ALCL, BIA-SCC, and breast implant-associated B-cell lymphoma. Together, these are the three recognized breast implant-associated malignancies.
| Cancer | Type | Primary Location | Implant Association |
|---|---|---|---|
| BIA-ALCL | T-cell lymphoma (immune system cancer) | Fluid surrounding implant; capsule tissue | Textured implants — especially macro-textured surfaces |
| BIA-SCC | Squamous cell carcinoma | Capsule tissue adjacent to implant | Reported across implant types; mechanism under investigation |
| BIA-B-Cell Lymphoma | B-cell lymphoma (immune system cancer) | Capsule tissue and periprosthetic fluid | The third recognized category; far rarer than BIA-ALCL, still being characterized in the literature |
None of the three is breast cancer in the conventional sense. BIA-ALCL and BIA-B-cell lymphoma are lymphomas — cancers of the immune system — and BIA-SCC is a carcinoma arising in the squamous cells of the capsule. All three are distinct from the breast cancer that develops in breast glandular tissue.
All three are rare. All three are serious. Each is treated with en bloc capsulectomy — complete, intact removal of the implant and surrounding capsule as one sealed unit — which is the FDA-endorsed, NCCN-recommended surgical standard for BIA-ALCL and the emerging standard for BIA-SCC and BIA-B-cell lymphoma.
Breast Implant-Associated Anaplastic Large Cell Lymphoma
What Is BIA-ALCL?
BIA-ALCL is a cancer of the T-cells of the immune system. It develops in the fluid that accumulates between the breast implant and the surrounding scar tissue capsule, or within the capsule tissue itself. It is categorized as a type of non-Hodgkin lymphoma. When diagnosed at a localized stage and treated with complete en bloc capsulectomy, surgical cure is achievable in the majority of cases.
Incidence Is Rising — Updated 2026 Data
A 2026 SEER-based national analysis found age-adjusted BIA-ALCL incidence rising from 17.2 per 100 million person-years in 2021 to 26.9 in 2022 (Lowe LS, Kim DK, Rohde CH, et al. J Natl Cancer Inst. 2026) — increasing rapidly and exceeding earlier FDA case-based estimates, which ranged from roughly 1 in 3,000–30,000 for specific high-risk textured devices to about 1 in 2,207–86,029 for textured implants overall. This is one reason ongoing vigilance and prompt evaluation of any late seroma or mass remains essential, regardless of how long ago an implant was placed.
How BIA-ALCL Develops
The leading pathogenesis model implicates chronic peri-implant inflammation — plausibly driven by bacterial biofilm colonizing the textured device surface — which sustains a Th17/Th1-skewed immune response at the capsule interface. Over years of this chronic inflammatory stimulation, acquired mutations in the JAK-STAT signaling pathway (most often involving JAK1 and STAT3) accumulate in T-cells at that site, driving monoclonal T-cell proliferation. The result is the CD30-positive, ALK-negative T-cell lymphoma that defines BIA-ALCL.
Risk Factors
| Risk Factor | Detail |
|---|---|
| Implant surface texture | Textured implants — especially macro-textured (BIOCELL) — carry the highest documented risk |
| Smooth implants | Rarely implicated; predominantly a textured implant disease |
| Implant fill type | Reported with both silicone and saline textured implants |
| Implant age at diagnosis | Median presentation approximately 7–10 years after placement |
| Prior BIA-ALCL | Incomplete surgical removal is the primary driver of recurrence |
Signs and Symptoms
The most common early symptom is late seroma — a fluid collection developing around the implant more than one year after placement, without an obvious cause such as injury or infection.
- ✓Late seroma — swelling or fluid accumulation developing years after placement
- ✓Breast enlargement or asymmetry not explained by weight change
- ✓Breast firmness or a new palpable mass near the implant
- ✓Skin changes, rash, or thickening around the breast
- ✓Swollen lymph nodes in the axilla (armpit)
Diagnostic Workup
Following the NCCN v2.2026 diagnostic algorithm, any late effusion (developing more than one year after implantation) or new periprosthetic mass triggers a structured workup:
Imaging — ultrasound of the breast and axilla is first-line; breast MRI or FDG-PET/CT is used in selected cases, since T-cell lymphomas often have extranodal disease that CT alone under-images
Fluid aspiration (FNA) — periprosthetic fluid is targeted for at least 50 mL for cytology and cell block, and at least 10 mL for flow cytometry; serial small-volume aspirations dilute tumor burden, so larger-volume sampling gives a more accurate diagnosis
Immunohistochemistry / flow cytometry panel — CD2, CD3, CD4, CD5, CD7, CD8, CD30, CD45, and ALK are evaluated; BIA-ALCL is CD30-positive and ALK-negative
Second pathology opinion — equivocal cases are referred for a second pathology consultation at a tertiary cancer center before a treatment plan is finalized
BIA-ALCL Staging
| Stage | Disease Location | Surgical Approach |
|---|---|---|
| IA | Fluid only — no capsule involvement, no mass | Total en bloc capsulectomy with contralateral implant removal; often curative without chemotherapy |
| IB | Capsule involvement, no mass, no lymph node spread | Total en bloc capsulectomy with contralateral implant removal; potentially curative without chemotherapy |
| IC | Capsule involvement with mass confined to capsule | Total en bloc capsulectomy + mass excision, with contralateral implant removal; often curative without chemotherapy |
| II | Regional lymph node involvement | En bloc surgery + lymph node surgery, coordinated with medical oncology/hematology for systemic therapy |
| III/IV | Spread beyond regional nodes | Multidisciplinary management coordinated with medical oncology/hematology (systemic therapy ± radiation); surgical role defined by that team |
For localized disease (Stage IA–IC), complete surgical excision — total capsulectomy with en-bloc removal of the implant and any mass, plus removal of the contralateral implant — is often curative, generally without chemotherapy. Contralateral (opposite-side) disease involvement occurs in approximately 4.6% of cases (Clemens MW, Medeiros LJ, Butler CE, et al. J Clin Oncol. 2016;34:160–168), which is why the contralateral implant is removed even when that side appears uninvolved. Extended disease (Stage II–IV) — capsular invasion beyond the capsule, a mass, or nodal/distant spread — requires multidisciplinary management. Dr. Whitfield’s practice provides the surgical management and coordinates that care; systemic therapy (CHOP or CHOP-like regimens, or brentuximab vedotin-based regimens) with or without radiation for residual disease is referred to and directed by medical oncology/hematology. This practice is not positioned as a chemotherapy or oncology treatment center.
Follow-up after treatment includes history and physical examination every 3–6 months for 2 years, with surveillance imaging no more than every 6 months for 2 years.
Confirmed cases of BIA-ALCL are reportable to the FDA MedWatch program and to the PROFILE registry (www.thepsf.org/PROFILE), which tracks patient outcomes and post-market surveillance data.
Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC)
BIA-SCC is a carcinoma arising in the squamous cells of the capsule tissue surrounding a breast implant. The FDA issued a safety communication on BIA-SCC in September 2022. Unlike BIA-ALCL, the implant types involved include a broader range of surfaces.
BIA-SCC is significantly rarer than BIA-ALCL — fewer than 30 cases had been reported globally at the time of the FDA’s 2022 safety communication. Several reported cases had aggressive clinical behavior.
Any late seroma or unexplained capsule change warrants complete pathological evaluation regardless of which implant-associated cancer is suspected.
En Bloc Capsulectomy as the Standard of Care
For both BIA-ALCL and BIA-SCC, the surgical treatment is en bloc capsulectomy — complete, intact removal of the implant and surrounding capsule as one sealed unit, without opening or disrupting the capsule during surgery.
| Surgical Approach | Oncologic Adequacy |
|---|---|
| Simple implant removal (capsule left in place) | Unacceptable — leaves the primary tumor site entirely |
| Total capsulectomy (capsule removed in pieces) | Insufficient — does not meet NCCN oncologic standards |
| En bloc capsulectomy (capsule never opened) | FDA-endorsed and NCCN-recommended standard |
What Complete En Bloc Resection Requires
Pre-operative planning — MRI or ultrasound to map fluid, masses, and capsule extent
Circumferential dissection — entire capsule freed without entering it
Intact removal — implant, fluid, and capsule removed as one specimen
Intraoperative containment — fluid does not contact the surgical field
Pathological analysis — reviewed by hematopathologist experienced with BIA-ALCL
Documentation of surgical margins — complete excision confirmed
PCR Pathology on Every Specimen
Every capsule removed at Dr. Whitfield’s practice is sent for PCR-based molecular pathology — 16S rRNA gene sequencing. In Dr. Whitfield’s published research, 29% of 694 consecutive capsule specimens tested positive for bacterial contamination, with 103 distinct bacterial species identified. Standard culture testing detected none.
Why Choose Dr. Whitfield for Breast Implant-Associated Cancer Surgery
| Credential | Detail |
|---|---|
| Board Certification | American Board of Plastic Surgery, FACS |
| Explant procedures | 2,000+ — including en bloc for confirmed and suspected BIA-ALCL |
| PCR capsule research | Largest series in medical literature — 694 specimens, 103 bacterial species, 29% contamination |
| FDA testimony | Testified before the U.S. General and Plastic Surgery Devices Panel |
| En bloc capsulectomy | Standard technique for all oncologic indications |
| Patients served | 40+ states and 15 countries |
Frequently Asked Questions About Breast Implant-Associated Cancers
What is BIA-ALCL?
+
BIA-ALCL stands for Breast Implant-Associated Anaplastic Large Cell Lymphoma. It is a rare type of T-cell lymphoma that can develop in the scar tissue and fluid surrounding a breast implant. It is not breast cancer, but rather a cancer of the immune system.
What are the symptoms of BIA-ALCL?
+
The most common symptom is a persistent swelling or pain in the vicinity of the breast implant, often developing years after the initial surgery. Other signs can include a lump in the breast or armpit, or skin rash. Any new changes around your implants should be evaluated by a physician.
Are some implants higher risk for BIA-ALCL?
+
Yes, the risk of BIA-ALCL is most strongly associated with textured-surface breast implants. The FDA has requested the recall of certain textured implants due to this association. However, it has been reported in all implant types, so ongoing vigilance is important for all patients.
What is BIA-SCC?
+
BIA-SCC, or Breast Implant-Associated Squamous Cell Carcinoma, is another rare but aggressive cancer that can arise in the capsule around breast implants. Unlike BIA-ALCL, it is an epithelial-based tumor. The FDA has issued safety communications to raise awareness of this potential risk.
How are breast implant-associated cancers diagnosed?
+
Diagnosis typically involves imaging (like an ultrasound or MRI) to assess fluid collection or masses, followed by a biopsy. For suspected BIA-ALCL, the fluid and capsule tissue must be tested for a specific marker called CD30 to confirm the diagnosis.
What is the treatment for BIA-ALCL?
+
When caught early and confined to the capsule, the standard treatment for BIA-ALCL is surgery to remove the implant and the entire capsule (en bloc or total capsulectomy). In more advanced cases, chemotherapy and radiation may be necessary.
Should I have my implants removed to prevent cancer?
+
This is a personal decision that should be made in consultation with a board-certified plastic surgeon. While the absolute risk is low, if you are concerned about BIA-ALCL or BIA-SCC, discussing the risks and benefits of explant surgery is a reasonable step.
How can I monitor for these cancers?
+
Regular self-exams and routine follow-up with your plastic surgeon are important. If you have textured implants, the FDA recommends periodic screening. Any new or unusual symptoms, such as swelling, pain, or lumps, should be promptly reported to your doctor for evaluation.
Next Steps
If you have textured breast implants and are experiencing late seroma, unexplained breast asymmetry, or any new breast changes — prompt evaluation is appropriate. Virtual consultations are available for patients outside Austin.
You Deserve a Surgeon Who Prepares You, Not Just Operates on You.
Dr. Robert Whitfield has guided thousands of patients through surgical decisions with clarity, data, and a personalized plan. Your consultation is where that plan begins.
Not ready to book? Download the free Inflammation Support Guide to start your journey.